Vasamed Inc (VSMD) 股票價格預測

Väsamed, Inc. engages in the design, licensing, manufacture, and distribution of a range of non-invasive hemodynamic technologies for vascular, wound care, cardiovascular and emergency medicine diagnostics. The company is headquartered in Minneapolis, Minnesota. Its SensiLase peripheral arterial disease (PAD)-IQ Studycast System provides measurement of tissue perfusion of the extremities particularly in patients with combined peripheral arterial disease and diabetes. The SensiLase PAD-IQ Studycast supports non-invasive upper and lower extremity vascular assessments, including skin perfusion pressure microcirculation pulse volume recording and ankle brachial index (ABI) calculation for doppler-obtained pressures; data sorting and customization options to support database mining, and wound imaging and surface area calculation featuring SmartDraw. SensiLase PAD-IQ System featuring Studycast Data Management offers health professionals various support tools for both PAD and critical limb ischemia. Its AcQtrac System technology is designed to measure cardiac and hemodynamic parameters.